BRIEF published on 08/08/2024 at 22:20, 1 year 7 months ago Nanobiotix: Information on Voting Rights and Shares as of July 31, 2024 Share Capital Voting Rights Actions Sotck Exchange NANOBIOTIX
PRESS RELEASE published on 08/08/2024 at 22:15, 1 year 7 months ago Voting Rights and Shares Capital of the Company Nanobiotix announces monthly publication of voting rights and shares capital in compliance with French Commercial Code. Learn more about the company's disruptive biotechnology approaches Voting Rights French Commercial Code Biotechnology Shares Capital NANOBIOTIX
BRIEF published on 07/09/2024 at 22:20, 1 year 8 months ago Voting Rights and Shares Capital of Nanobiotix Voting Rights Shares Euronext Nasdaq NANOBIOTIX
PRESS RELEASE published on 07/09/2024 at 22:15, 1 year 8 months ago Voting Rights and Shares Capital of the Company Nanobiotix discloses voting rights and shares capital information as per French Commercial Code. Check the latest figures for June 30, 2024 Euronext Paris Voting Rights French Commercial Code Shares Capital NANOBIOTIX
BRIEF published on 07/03/2024 at 15:54, 1 year 8 months ago Threshold crossings at NANOBIOTIX by Goldman Sachs Group AMF Goldman Sachs NANOBIOTIX Threshold Crossings
BRIEF published on 06/12/2024 at 22:20, 1 year 9 months ago Nanobiotix hosts virtual discussion on the potential of NBTXR3 in cancer treatments Immunotherapy Head And Neck Cancer NANOBIOTIX NBTXR3 Virtual Discussion
PRESS RELEASE published on 06/12/2024 at 22:15, 1 year 9 months ago NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024 Nanobiotix to host virtual KOL event discussing NBTXR3 combined with immunotherapy in head and neck cancer and beyond on June 18, 2024 Immunotherapy Head And Neck Cancer NANOBIOTIX NBTXR3 Virtual KOL Event
BRIEF published on 06/11/2024 at 22:20, 1 year 9 months ago Nanobiotix: Monthly Information on Voting Rights and Shares Voting Rights Euronext Actions Nasdaq NANOBIOTIX
PRESS RELEASE published on 06/11/2024 at 22:15, 1 year 9 months ago Voting Rights and Shares Capital of the Company Nanobiotix discloses its voting rights and shares capital information as of May 31, 2024, in compliance with regulatory requirements. The company is a clinical biotechnology firm listed on Euronext Paris and Nasdaq Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
BRIEF published on 06/02/2024 at 16:05, 1 year 9 months ago Nanobiotix Announces Promising Data on NBTXR3 for Head and Neck Cancer Patients Clinical Trial Head And Neck Cancer NANOBIOTIX NBTXR3 ASCO
Published on 03/17/2026 at 21:30, 20 minutes ago Rainy Mountain Announces Appointment of Colton Griffith to Board of Directors
Published on 03/17/2026 at 13:30, 8 hours 20 minutes ago Hillcrest Energy Technologies Confirms ZVS PCS1000 Prototype on Track for June 2026
Published on 03/17/2026 at 13:30, 8 hours 20 minutes ago Namibia Critical Metals Welcomes Toyota Tsusho as Strategic Partner in the Lofdal Heavy Rare Earths Project
Published on 03/17/2026 at 13:00, 8 hours 50 minutes ago Avant Brands Announces Strategic Realignment of European Operations and Reclaims BLK MKT Brand Rights in Germany and Switzerland
Published on 03/17/2026 at 21:21, 29 minutes ago KION GROUP AG successfully places a bond of € 500 million
Published on 03/17/2026 at 20:55, 55 minutes ago EQS-Adhoc: thyssenkrupp nucera lowers its sales and EBIT outlook for the Group and the gH2 segment for FY 2025/26 due to higher project costs
Published on 03/17/2026 at 17:58, 3 hours 52 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/17/2026 at 07:00, 14 hours 50 minutes ago Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 1 day 3 hours ago Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 1 day 3 hours ago Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 1 day 3 hours ago Reporting on share buyback transactions carried out between March 9 and March 13, 2026
